Street Calls of the Week
SAN CARLOS, Calif. - On Wednesday, BeOne Medicines Ltd. (NASDAQ:ONC) reported second quarter revenue that exceeded analyst expectations, though earnings fell short of estimates.
The company’s stock slipped 0.42% in pre-market trading following the announcement.
The global oncology company posted revenue of $1.32 billion for the second quarter of 2025, surpassing the consensus estimate of $1.24 billion and representing a 42% increase YoY. However, adjusted earnings per share came in at $0.17, missing analyst expectations of $0.21. Total (EPA:TTEF) product revenue rose 41% to $1.3 billion, driven primarily by strong BRUKINSA sales.
BRUKINSA (zanubrutinib) continued its strong performance with global sales increasing 49% to $950 million compared to the second quarter of 2024. In the U.S., BRUKINSA sales reached $684 million, up 43% YoY, while European sales surged 85% to $150 million.
"Our strong second quarter performance reinforces our trajectory as a global oncology powerhouse and underscores our proven ability to deliver sustainable, long-term growth," said John V. Oyler, Co-Founder, Chairman and CEO of BeOne.
The company updated its full-year 2025 revenue guidance to $5.0-$5.3 billion, compared to the previous range of $4.9-$5.3 billion. The midpoint of $5.15 billion is slightly above the analyst consensus of $5.132 billion.
BeOne expects to achieve more than 20 R&D milestones in the next 18 months across its hematology and solid tumor pipeline. The company’s gross margin as a percentage of global product sales improved to 87.4% from 85.0% in the prior-year period.
TEVIMBRA (tislelizumab) sales totaled $194 million in the quarter, representing 22% growth compared to the same period last year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.